Core Scientific, Inc.
CORZQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $142 | $113 | $127 | $121 |
| % Growth | 25.7% | -11% | 5.2% | – |
| Cost of Goods Sold | $103 | $97 | $90 | $100 |
| Gross Profit | $39 | $15 | $37 | $20 |
| % Margin | 27.7% | 13.7% | 29.1% | 17% |
| R&D Expenses | $2 | $2 | $2 | $1 |
| G&A Expenses | $24 | $24 | $24 | $22 |
| SG&A Expenses | $28 | $25 | $25 | $23 |
| Sales & Mktg Exp. | $4 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $30 | $27 | $27 | $24 |
| Operating Income | $9 | -$12 | $9 | -$4 |
| % Margin | 6.6% | -10.7% | 7.4% | -3.1% |
| Other Income/Exp. Net | -$205 | -$29 | -$19 | -$8 |
| Pre-Tax Income | -$195 | -$41 | -$9 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$196 | -$41 | -$9 | -$12 |
| % Margin | -137.9% | -36.4% | -7.3% | -9.7% |
| EPS | -0.512 | -0.11 | -0.025 | -0.031 |
| % Growth | -365.5% | -347.2% | 20.9% | – |
| EPS Diluted | -0.512 | -0.11 | -0.025 | -0.031 |
| Weighted Avg Shares Out | 382 | 382 | 376 | 375 |
| Weighted Avg Shares Out Dil | 382 | 382 | 376 | 375 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $84 | $2 | $0 | $0 |
| Depreciation & Amortization | $31 | $24 | $21 | $20 |
| EBITDA | $39 | -$15 | $49 | $9 |
| % Margin | 27.3% | -13.3% | 38.9% | 7.4% |